ライフサイエンスコーパス: entecavir

1 ith a high barrier to resistance (tenofovir, entecavir).

2 mtricitabine, tenofovir, and, more recently, entecavir.

3 ents showed that M184V confers resistance to entecavir.

4 efovir 15% (5 of 33), tenofovir 0% (0 of 3), entecavir 0% (0 of 1), and 5% (1 of 20) for those not gi

5 eAg-positive CHB patients were randomized to entecavir 0.5 mg (n = 354) or lamivudine 100 mg (n = 355

6 Entecavir, a drug approved by the Food and Drug Administ

7 Birinapant enhances the ability of entecavir, an antiviral nucleoside analog, to reduce vir

8 We evaluated continued entecavir and lamivudine treatment through 96 weeks.

9 ng-term viral suppression can be obtained by entecavir and tenofovir even in cases of multidrug resis

10 Entecavir and tenofovir were shown to be effective in su

11 of nucleos(t)ide analogs and agents such as entecavir and tenofovir with high potency and high genet

12 nts including tenofovir disoproxil fumarate, entecavir, and telbivudine offer greater potency than la

13 ocumented HBV reactivation were treated with entecavir at a dosage of 0.5 mg/day for 48 weeks.

14 Entecavir (BMS-200475) was synthesized from 4-trimethyls

15 Entecavir can be given safely for a short time and cause

16 1-resistance patterns and their selection by entecavir, caution is needed with the use of entecavir i

17 In the entecavir cohort, 2 (1.37%) of 145 patients experienced

18 eron, adefovir monotherapy and adefovir plus entecavir combination.

19 Entecavir demonstrated superior benefit to lamivudine at

20 BACKGROUND & AIMS: Entecavir (ETV) and tenofovir disoproxil fumarate (TDF)

21 3 years of therapy with telbivudine (LdT) or entecavir (ETV) and to assess predictive factors for eGF

22 omly assigned to receive either prophylactic entecavir (ETV) before chemotherapy to 3 months after co

23 Entecavir (ETV) is a guanosine nucleoside analogue with

24 Entecavir (ETV) is a potent inhibitor of hepatitis B vir

25 The novel 2'-deoxyguanosine analog Entecavir (ETV) is a potent inhibitor of hepatitis B vir

26 side analog inhibitor of viral DNA synthesis entecavir (ETV) reduced hepatocyte turnover during clear

27 Entecavir (ETV) resistance (ETVr) results from HBV rever

28 Virologic resistance emerging during entecavir (ETV) therapy for hepatitis B virus (HBV) requ

29 ic antiviral resistance was performed on 673 entecavir (ETV)-treated nucleoside naive hepatitis B vir

30 onic hepatitis B (CHB) patients treated with entecavir (ETV).

31 Entecavir (ETV; Baraclude) is a novel deoxyguanosine ana

32 nfections numerically, whereas tenofovir and entecavir had no cases and may be more effective, but th

33 comparatively high and both telbivudine and entecavir have decreased efficacy against lamivudine-res

34 ore potent nucleoside analogs (tenofovir and entecavir) have proven to have much lower rates of antiv

35 his study was to investigate the efficacy of entecavir in chronic hepatitis D (CHD).

36 entecavir, caution is needed with the use of entecavir in persons with HIV-1 and HBV coinfection who

37 Entecavir is a nucleoside analog with potent antiviral e

38 Entecavir is a potent antiviral agent with a low rate of

39 Entecavir is a potent antiviral for nucleoside-naive pat

40 e obtained supportive in vitro evidence that entecavir is a potent partial inhibitor of HIV-1 replica

41 We observed that entecavir led to a consistent 1-log(10) decrease in HIV-

42 The peginterferon and entecavir monotherapy groups also differed in HCC incide

43 Long-term entecavir monotherapy is highly effective at preventing

44 alysis showed that in one of these patients, entecavir monotherapy led to an accumulation of HIV-1 va

45 s B liver transplant recipients treated with entecavir monotherapy without hepatitis B immune globuli

46 In patients exposed to entecavir (n = 102), full resistance was present in 35.3

47 Patients continuing in year 2 (entecavir, n = 243; lamivudine, n = 164) were assessed f

48 titis B immunoglobulin (HBIG), or lamivudine+entecavir on direct sequencing were cloned after nested

49 resistance as a first-line therapy, such as entecavir or tenofovir, provides the best chance of achi

50 alogues with lower resistance rates, such as entecavir or tenofovir, suppress hepatitis B virus (HBV)

51 h rate of antiviral resistance compared with entecavir or tenofovir.

52 n (CHB) with the nucleos(t)ide analogs (NAs) entecavir or tenofovir.

53 This study assessed a pilot study of entecavir plus low-dose, on-demand HBIg in preventing HB

54 Entecavir plus low-dose, on-demand HBIg resulted in a lo

55 ents undergoing HBV-related LT and receiving entecavir plus low-dose, on-demand HBIg were enrolled an

56 Surprisingly, during entecavir plus tenofovir combination, anti-HBe seroconve

57 Giving the mice the nucleoside analogue entecavir reduced viral loads and decreased liver inflam

58 nt experienced virologic breakthrough due to entecavir resistance.

59 esistance mutation V173L (in 5 samples), the entecavir-resistance mutations T184S (in 2 samples) and

60 Entecavir successfully suppressed HBV DNA to undetectabl

61 ucleotide analogs, lamivudine, adefovir, and entecavir, suppress HBV replication and are extremely we

62 assessed the HCC incidence beyond year 5 of entecavir/tenofovir (ETV/TDF) therapy and tried to deter

63 Similar proportions of entecavir-treated and lamivudine-treated patients achiev

64 cing of the viral genome was performed on 11 entecavir-treated and pegylated interferon (peginterfero

65 Viral loads of entecavir-treated patients were constantly suppressed to

66 ntigen truncation mutations were detected in entecavir-treated patients with HCC but not in peginterf

67 P = .022 for comparison of peginterferon- vs entecavir-treated patients).

68 Higher proportions of entecavir-treated than lamivudine-treated patients achie

69 rmed HBeAg seroconversion occurred in 31% of entecavir-treated versus 25% of lamivudine-treated patie

70 Among patients treated in year 2, 74% of entecavir-treated versus 37% of lamivudine-treated patie

71 polymerase chain reaction (PCR), and 79% of entecavir-treated versus 68% of lamivudine-treated patie

72 One year of entecavir treatment is ineffective in CHD.

73 Entecavir treatment through 96 weeks results in continue

74 t of normal) occurred in 4 patients, despite entecavir treatment.

75 CD38+ MAIT cells in blood, which declined on entecavir treatment.

76 Nine patients were sampled before and on entecavir treatment.

77 dy in chimeric mice harboring the lamivudine/entecavir triple mutant, FMCAP effectively reduced HBV v

78 0M/rtM204V) mutants as well as in lamivudine/entecavir triple mutants (L180M+S202G+M204V) in vitro.

79 patitis B e antibody and about the safety of entecavir versus tenofovir.

80 Entecavir was given at a dosage of 1 mg/d for 1 year.

81 AP effectively reduced HBV viral load, while entecavir was not effective.